A new application about 566169-93-5

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Quality Control of: 2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol. In my other articles, you can also check out more blogs about 566169-93-5

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 566169-93-5, Name is 2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol, molecular formula is C14H12N2OS. In a Review£¬once mentioned of 566169-93-5, Quality Control of: 2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol

Alzheimer’s disease (AD), the most common form of dementia, is a progressive and fatal neurodegenerative disorder. The neuropathological hallmarks of AD generally revealed on postmortem brain tissue are the extracellular neuritic plaque deposits and intracellular neurofibrillary tangles. Significant evidence supports the pivotal role of beta-amyloid peptides in the pathogenesis of AD. Therefore, The ability to image beta-amyloid plaques in brain with noninvasive techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) may not only aid in presymptomatic identification of AD patients and differential diagnosis of patients with dementia, but also monitoring the effectiveness of anti-amyloid therapeutic strategies. For these reasons, development of beta-amyloid plaquespecific imaging agents has been extensively pursued and reported. This review summarizes the current status of 18F-labeled radioligand development for PET imaging of beta-amyloid plaques. [18F]FDDNP is the first PET radioligand that demonstrated differential uptake and retention in the brain of AD patients, while a low signal-to-noise ratio in PET studies was indicated. At this time, [18F]3′-F-PIB (flutemetamol), [18F]AV-1 (florbetaben), [18F]AZD4694, and [18F]MK-3328 are undergoing phase II and III clinical trial. [18F]AV-45 (florbetapir) has recently been approved by FDA for use in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. Several other 18F-labeled radioligands based upon imidazo[1,2-a]pyridine, benzothiazole, stilbene, benzofuran, and benzoxazole core structures have also been synthesized and evaluated.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Quality Control of: 2-(4-(Methylamino)phenyl)benzo[d]thiazol-6-ol. In my other articles, you can also check out more blogs about 566169-93-5

Reference£º
Thiazole | C3H481NS – PubChem,
Thiazole | chemical compound | Britannica